WT1 and hepatocellular carcinoma: This checkpoint blockade can potentially restore and amplify innate and adaptive immune responses, making it an ideal complement to DC and NK cell therapies [1]. This case report explores the synergistic potential of combining these therapies in the treatment of advanced hepatocellular carcinoma (HCC), focusing on the biological rationale and clinical outcomes of this multi-modal approach using DC vaccines targeting WT1 and α-Galcer, NK cell therapy, and Nivolumab.